Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VALN Stock Forecast 2026-2027
$5.39
Current Price
$507.78M
Market Cap
Buy 3
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to VALN Price Targets
+234.0%
To High Target of $18.00
+141.2%
To Median Target of $13.00
-10.9%
To Low Target of $4.80
VALN Price Momentum
+1.5%
1 Week Change
-5.1%
1 Month Change
-11.2%
1 Year Change
-38.9%
Year-to-Date Change
-56.0%
From 52W High of $12.25
+6.5%
From 52W Low of $5.06
📊 TOP ANALYST CALLS
Did VALN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Valneva is one of their latest high-conviction picks.
Latest VALN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, VALN has a bullish consensus with a median price target of $13.00 (ranging from $4.80 to $18.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $5.39, the median forecast implies a 141.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 234.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VALN Analyst Ratings
3
Buy
0
Hold
1
Sell
VALN Price Target Range
Low
$4.80
Average
$13.00
High
$18.00
Current: $5.39
Latest VALN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VALN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 8, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $13.00 |
| Aug 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 19, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $18.00 |
| May 8, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Apr 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 9, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 2, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 24, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 24, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 19, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 5, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 23, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 11, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 25, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Valneva SE (VALN) Competitors
The following stocks are similar to Valneva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Valneva SE (VALN) Financial Data
Valneva SE has a market capitalization of $507.78M with a P/E ratio of 72.7x. The company generates $180.90M in trailing twelve-month revenue with a -88.3% profit margin.
Revenue growth is -37.2% quarter-over-quarter, while maintaining an operating margin of -76.7% and return on equity of -109.6%.
Valuation Metrics
Market Cap
$507.78M
Enterprise Value
$672.70M
P/E Ratio
72.7x
PEG Ratio
0.4x
Price/Sales
3.2x
Growth & Margins
Revenue Growth (YoY)
-37.2%
Gross Margin
+15.3%
Operating Margin
-76.7%
Net Margin
-88.3%
EPS Growth
-37.2%
Financial Health
Cash/Price Ratio
+21.9%
Current Ratio
2.1x
Debt/Equity
273.2x
ROE
-109.6%
ROA
-14.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Valneva SE (VALN) Business Model
About Valneva SE
What They Do
Develops vaccines for infectious diseases.
Business Model
Valneva SE generates revenue through the development and commercialization of vaccines, focusing on unmet medical needs in infectious disease prevention. The company targets both travel-related and endemic diseases, with notable offerings like its COVID-19 vaccine, VLA2001, and ongoing projects for diseases such as Lyme and chikungunya.
Additional Information
Headquartered in France, Valneva collaborates with governments and health organizations, highlighting its strategic role in enhancing public health and pandemic preparedness. The company's expertise in vector-borne diseases positions it as a vital player in diversifying vaccine options and addressing global health challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
713
CEO
Mr. Thomas Lingelbach
Country
France
IPO Year
2021
Website
valneva.comValneva SE (VALN) Latest News & Analysis
Latest News
Quick Summary
Valneva SE will hold its Annual General Meeting on June 25, 2026, at 2:00 p.m. CEST in Lyon, France. Documentation for the meeting is now available.
Why It Matters
Valneva SE's Annual General Meeting may provide insights on strategic direction, financial performance, and future projects, influencing investor confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Valneva SE will hold investor meetings and presentations at various conferences in the U.S. and Europe in June 2026, as announced on May 28, 2026.
Why It Matters
Valneva's management presentations may signal upcoming developments or strategic plans, potentially impacting stock performance and investor sentiment in the specialty vaccine sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Valneva Q1 Earnings Call Highlights
1 month ago
Quick Summary
Valneva (NASDAQ: VALN) reported lower Q1 2026 revenue and a wider loss, focusing on cash conservation as it awaits regulatory updates for its Lyme disease vaccine with Pfizer.
Why It Matters
Valneva's lower revenue and wider losses may signal financial instability, while cash conservation efforts indicate a cautious approach amid pending regulatory outcomes for its Lyme disease vaccine.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
Valneva SE reported its Q1 2026 financial results and updated its 2026 financial guidance on May 13, 2026. Detailed results are available on the company's website.
Why It Matters
Valneva's Q1 financial results and updated guidance can impact stock performance, reflecting its operational health and future growth potential, influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Valneva SE (VALN) held its Q1 2026 earnings call, discussing financial performance and future outlook. Further details on financial results and strategic plans were provided during the call.
Why It Matters
Valneva's Q1 2026 earnings reveal financial health, growth potential, and strategic direction, influencing stock performance and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
1 month ago
Quick Summary
Pomerantz LLP is investigating claims for Valneva SE (NASDAQ: VALN) investors. Interested parties can contact Danielle Peyton for more information.
Why It Matters
Pomerantz LLP's investigation into Valneva SE may indicate potential legal issues, impacting the company's stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VALN Stock
What is Valneva SE's (VALN) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Valneva SE (VALN) has a median price target of $13.00. The highest price target is $18.00 and the lowest is $4.80.
Is VALN stock a good investment in 2026?
According to current analyst ratings, VALN has 3 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $5.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VALN stock?
Wall Street analysts predict VALN stock could reach $13.00 in the next 12 months. This represents a 141.2% increase from the current price of $5.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Valneva SE's business model?
Valneva SE generates revenue through the development and commercialization of vaccines, focusing on unmet medical needs in infectious disease prevention. The company targets both travel-related and endemic diseases, with notable offerings like its COVID-19 vaccine, VLA2001, and ongoing projects for diseases such as Lyme and chikungunya.
What is the highest forecasted price for VALN Valneva SE?
The highest price target for VALN is $18.00 from Brandon Folkes at HC Wainwright & Co., which represents a 234.0% increase from the current price of $5.39.
What is the lowest forecasted price for VALN Valneva SE?
The lowest price target for VALN is $4.80 from at , which represents a -10.9% decrease from the current price of $5.39.
What is the overall VALN consensus from analysts for Valneva SE?
The overall analyst consensus for VALN is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $13.00.
How accurate are VALN stock price projections?
Stock price projections, including those for Valneva SE, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 4:02 AM UTC